Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
Diffuse brainstem glioma carries a dismal prognosis. The current cornerstone of treatment is radiation therapy. Chemotherapy appears to be ineffective and the role of this treatment in the recurrent or progressive setting is not known. Bevacizumab and irinotecan have been reported to have shown radiographic response and improvement in progression-free survival among patients with malignant supratentorial gliomas. In this paper, we report our experience in an adult patient with progressive diffuse brainstem glioma treated with bevacizumab and irinotecan.
Torcuator
Roy
R
Department of Neurosurgery, Henry Ford Health System, Hermelin Brain Tumor Center, Detroit, MI, USA. nsroy@neuro.hfh.edu
Zuniga
Richard
R
Loutfi
Randa
R
Mikkelsen
Tom
T
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D020295:Brain Stem Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003131:Combined Modality Therapy; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D000077146:Irinotecan; D008279:Magnetic Resonance Imaging; D011878:Radiotherapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D002166:Camptothecin